Savara Inc. (SVRA)
Develops inhaled treatments for rare lung diseases like pulmonary alveolar proteinosis.
$5.33-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+105.8%
The outlook
Analysts strongly favor SVRA, with an average price target about double the current price of $5.33. The stock sits below both its 50- and 200-day moving averages, suggesting near-term weakness, though it's positioned roughly midway through its 52-week range. Overall sentiment leans bullish despite the recent downward price trend.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range63% of the way from its 52-week low to high
Price targetAvg target +105% vs current price
Analyst price target
~12-month · 8 analysts$10.94average target+105.2% vs now
Now $5.33
Low $9.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.09B
52-wk high
$7.01
52-wk low
$2.43
50-day avg
$5.51
200-day avg
$5.37
Trailing P/E
—